Daniele Tienforti, Malvina Hoxha, Alfonso Boris Di Pasquale, Vinicio Rizza, Arcangelo Barbonetti
{"title":"佩罗尼氏病营养保健品干预证据分析:基于指南的批判性综述。","authors":"Daniele Tienforti, Malvina Hoxha, Alfonso Boris Di Pasquale, Vinicio Rizza, Arcangelo Barbonetti","doi":"10.1093/sxmrev/qeae038","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The management of Peyronie's disease (PD) is a challenge for the clinician. Despite the lack of etiologic therapy, different nonsurgical approaches have often been empirically proposed. The most used treatment is based on nutraceutical drugs with antioxidant activity, although such an intervention remains controversial.</p><p><strong>Objectives: </strong>We reviewed the evidence from the randomized controlled trials included in the recommendations of the American Urological Association (AUA), Canadian Urological Association (CUA), European Association of Urology, and International Society for Sexual Medicine.</p><p><strong>Methods: </strong>We searched PubMed, Scopus, Web of Science, and Cochrane Library for randomized controlled trials, reviews, and guidelines on nutraceutical interventions for PD.</p><p><strong>Results: </strong>Our analysis provides detailed information on potential interventions, underlying the inconsistent evidence. Acetyl esters of carnitine, although not recommended by any of the available guidelines, showed potential benefit in some selected studies. Omega-3 fatty acids are not recommended due to withdrawn study evidence. The CUA and AUA were the only societies to consider the use of coenzyme Q10. While the CUA suggested that it might be offered as a treatment option, the AUA refrained from taking a definitive stance due to insufficient evidence. Similarly, conflicting recommendations have been produced on potassium para-aminobenzoate. While the CUA considers potassium para-aminobenzoate potentially useful in slowing PD progression, the AUA deems the evidence insufficient. Conversely, both the International Society for Sexual Medicine and European Association of Urology do not recommend its use.</p><p><strong>Conclusion: </strong>This critical comparative analysis of the most recent guidelines produced by the leading scientific societies highlights some inconsistencies in the recommendations on nutraceutical intervention for PD, even within a background of overall ineffectiveness of this treatment approach.</p>","PeriodicalId":21813,"journal":{"name":"Sexual medicine reviews","volume":" ","pages":"747-753"},"PeriodicalIF":3.6000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Analysis of evidence on nutraceutical interventions for Peyronie's disease: a guideline-based critical review.\",\"authors\":\"Daniele Tienforti, Malvina Hoxha, Alfonso Boris Di Pasquale, Vinicio Rizza, Arcangelo Barbonetti\",\"doi\":\"10.1093/sxmrev/qeae038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The management of Peyronie's disease (PD) is a challenge for the clinician. Despite the lack of etiologic therapy, different nonsurgical approaches have often been empirically proposed. The most used treatment is based on nutraceutical drugs with antioxidant activity, although such an intervention remains controversial.</p><p><strong>Objectives: </strong>We reviewed the evidence from the randomized controlled trials included in the recommendations of the American Urological Association (AUA), Canadian Urological Association (CUA), European Association of Urology, and International Society for Sexual Medicine.</p><p><strong>Methods: </strong>We searched PubMed, Scopus, Web of Science, and Cochrane Library for randomized controlled trials, reviews, and guidelines on nutraceutical interventions for PD.</p><p><strong>Results: </strong>Our analysis provides detailed information on potential interventions, underlying the inconsistent evidence. Acetyl esters of carnitine, although not recommended by any of the available guidelines, showed potential benefit in some selected studies. Omega-3 fatty acids are not recommended due to withdrawn study evidence. The CUA and AUA were the only societies to consider the use of coenzyme Q10. While the CUA suggested that it might be offered as a treatment option, the AUA refrained from taking a definitive stance due to insufficient evidence. Similarly, conflicting recommendations have been produced on potassium para-aminobenzoate. While the CUA considers potassium para-aminobenzoate potentially useful in slowing PD progression, the AUA deems the evidence insufficient. Conversely, both the International Society for Sexual Medicine and European Association of Urology do not recommend its use.</p><p><strong>Conclusion: </strong>This critical comparative analysis of the most recent guidelines produced by the leading scientific societies highlights some inconsistencies in the recommendations on nutraceutical intervention for PD, even within a background of overall ineffectiveness of this treatment approach.</p>\",\"PeriodicalId\":21813,\"journal\":{\"name\":\"Sexual medicine reviews\",\"volume\":\" \",\"pages\":\"747-753\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sexual medicine reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/sxmrev/qeae038\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sexual medicine reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/sxmrev/qeae038","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
简介:治疗佩罗尼氏病(PD)是临床医生面临的一项挑战。尽管缺乏病因治疗,但人们经常根据经验提出不同的非手术治疗方法。最常用的治疗方法是使用具有抗氧化活性的营养保健药物,但这种干预方法仍存在争议:我们回顾了美国泌尿外科协会(AUA)、加拿大泌尿外科协会(CUA)、欧洲泌尿外科协会和国际性医学协会推荐的随机对照试验中的证据:我们检索了 PubMed、Scopus、Web of Science 和 Cochrane 图书馆中有关 PD 营养干预的随机对照试验、综述和指南:我们的分析提供了潜在干预措施的详细信息,这些信息隐藏在不一致的证据中。肉碱乙酰酯虽然未被任何现有指南推荐,但在一些选定的研究中显示出潜在的益处。奥米加-3 脂肪酸因研究证据被撤回而未被推荐。CUA和AUA是唯一考虑使用辅酶Q10的协会。CUA建议将辅酶Q10作为一种治疗选择,而AUA则因证据不足而未采取明确立场。同样,关于对氨基苯甲酸钾的建议也相互矛盾。CUA认为对氨基苯甲酸钾可能有助于延缓帕金森病的进展,而AUA则认为证据不足。相反,国际性医学会(International Society for Sexual Medicine)和欧洲泌尿学协会(European Association of Urology)都不建议使用对氨基苯甲酸钾:这项对主要科学协会最新指南进行的批判性比较分析突出表明,即使在这种治疗方法总体无效的背景下,有关营养保健品干预帕金森病的建议也存在一些不一致之处。
Analysis of evidence on nutraceutical interventions for Peyronie's disease: a guideline-based critical review.
Introduction: The management of Peyronie's disease (PD) is a challenge for the clinician. Despite the lack of etiologic therapy, different nonsurgical approaches have often been empirically proposed. The most used treatment is based on nutraceutical drugs with antioxidant activity, although such an intervention remains controversial.
Objectives: We reviewed the evidence from the randomized controlled trials included in the recommendations of the American Urological Association (AUA), Canadian Urological Association (CUA), European Association of Urology, and International Society for Sexual Medicine.
Methods: We searched PubMed, Scopus, Web of Science, and Cochrane Library for randomized controlled trials, reviews, and guidelines on nutraceutical interventions for PD.
Results: Our analysis provides detailed information on potential interventions, underlying the inconsistent evidence. Acetyl esters of carnitine, although not recommended by any of the available guidelines, showed potential benefit in some selected studies. Omega-3 fatty acids are not recommended due to withdrawn study evidence. The CUA and AUA were the only societies to consider the use of coenzyme Q10. While the CUA suggested that it might be offered as a treatment option, the AUA refrained from taking a definitive stance due to insufficient evidence. Similarly, conflicting recommendations have been produced on potassium para-aminobenzoate. While the CUA considers potassium para-aminobenzoate potentially useful in slowing PD progression, the AUA deems the evidence insufficient. Conversely, both the International Society for Sexual Medicine and European Association of Urology do not recommend its use.
Conclusion: This critical comparative analysis of the most recent guidelines produced by the leading scientific societies highlights some inconsistencies in the recommendations on nutraceutical intervention for PD, even within a background of overall ineffectiveness of this treatment approach.